Skip to content
Home/Companies/Healthcare / Biotech/GlycoVaxyn

GlycoVaxyn

Healthcare / Biotech·Switzerland·Exited 2015·Held 3yr
Entry
2012
Hold
3yr
Exit
2015

Who owns GlycoVaxyn?

GlycoVaxyn was owned by Sofinnova Partners through Sofinnova Capital VII (2012 vintage) from 2012 to 2015, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital VII · 2012 · Life Sciences VC

Key facts

HQSwitzerland
SectorHealthcare / Biotech
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2015

More from Sofinnova Capital VII

Other portfolio companies in the same fund.

Pixium Vision
Active
MedTechFrance· 2013
Advanced Perfusion Diagnostics
Exited 2019
MedTechFrance· 2012
to
Ascendis Pharma
Exited 2015
BiotechDenmark· 2012
EOS
Exited 2013
BiotechItaly· 2012
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track GlycoVaxyn

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on GlycoVaxyn.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue